The IIFL Securities Report: Buy Jubilant Ingrevia - April 10
IIFL Securities maintains a 'buy' rating on Jubilant Ingrevia with a target price of Rs 535, indicating a potential upside of around 4%. The current market price of Jubilant Ingrevia is Rs 514. The brokerage firm cites the company's strong financials, expansion plans, and favourable industry dynamics as key reasons for its bullish stance.
About Jubilant Ingrevia:
Jubilant Ingrevia Limited, formerly known as Jubilant Life Sciences Limited, is an Indian multinational pharmaceutical and life sciences company headquartered in Noida, Uttar Pradesh, India. The company operates through three segments: Pharmaceuticals, Life Science Ingredients, and Drug Discovery & Development Services. Jubilant Ingrevia manufactures and markets a wide range of pharmaceuticals, including active pharmaceutical ingredients (APIs), generic formulations, and branded generics. It also produces life science ingredients, such as vitamins, minerals, and nutraceuticals. Additionally, the company provides drug discovery and development services to pharmaceutical and biotechnology companies. Jubilant Ingrevia has a global presence with operations in over 40 countries and employing over 5,000 people worldwide.
52 Week Price Trend:
Jubilant Ingrevia (NSE: JUBLINGREA) is currently trading at Rs 514, close to its 52-week high of Rs 524.7. The stock has had a strong run in the past year, rising from its 52-week low of Rs 350.45. Jubilant Ingrevia is a specialty chemicals company that manufactures and sells a range of products, including life science ingredients, specialty polymers, and fine chemicals. The company has a global presence, with operations in India, Europe, and North America. Jubilant Ingrevia's strong performance in recent months has been driven by factors such as increased demand for its products, cost-cutting measures, and a favorable regulatory environment.
Stratzy's MOST Analysis:
JUBLINGREA has been assigned a BB- rating by Stratzy's MOST framework, indicating medium fundamental risks. This assessment is based on an evaluation of the company's Management, Outlook, Safety, and Trend. The BB- rating suggests that JUBLINGREA has some areas of concern, but overall presents a balanced risk profile. It is important to note that the MOST framework is just one approach to evaluating a company's fundamentals, and investors should consider a variety of factors before making investment decisions.
Company's Fundamentals:
Jubilant Ingrevia (NSE: JUBLINGREA) is a renowned producer of specialty chemicals, pharmaceuticals, and nutritional products. Its stock currently trades at a PE ratio of 37.66, indicating that investors are willing to pay 37.66 times the company's earnings for each share they own. The PB ratio of 2.87 suggests that the company's market value is 2.87 times its book value, indicating a premium over its net asset value. Meanwhile, the dividend yield of 1.03% represents the annual dividend payout as a percentage of the current stock price, offering investors a modest income stream from their investment.
Fundamental and Technical information provided in this blog were last updated on 10 Apr, 2024
Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.